Haeseong Park

Trials

Studies that name Haeseong Park as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:04 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT03326258 · Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

  National Cancer Institute (NCI) · withdrawn · Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative, GPNMB Positive · principal investigator
• Ph2
  NCT01928290 · Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

  Washington University School of Medicine · completed · Stomach Neoplasms, Esophageal Neoplasms · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Targeting Tryptophan Metabolism in Rectal Cancer
  R01CA278197 · NCI · WASHINGTON UNIVERSITY · fiscal years 2023 to 2026 · $274,115 awarded in 2026
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
  UM1CA186704 · NCI · DUKE UNIVERSITY · PI JAMES L. ABBRUZZESE, ELIZABETH CLAIRE DEES, Andrea Wang-Gillam · fiscal years 2014 to 2019
  Named on NCT03326258